SCHEMBL8608

SCHEMBL8608

Cc1oc2ccc(F)cc2c(=O)c1-c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
ALDH1A1 P00352 4/20 0.59
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
TNKS O95271 1/20 0.56
MAPT P10636 5/20 0.52
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
PKM P14618 1/20 0.49
RECQL P46063 1/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
GABRP O00591 5/20 0.48
GABRD O14764 5/20 0.48
GABRA1 P14867 5/20 0.48
GABRB1 P18505 5/20 0.48
GABRG2 P18507 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8670 0.90 GABRP (0.57) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL8860 0.84 KDM4E (0.58) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL8646 0.82 GABRP (0.56) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL11212 0.82 KDM4E (0.68) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL8364 0.81 MAPK14 (0.59) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL9070 0.81 ALDH1A1 (0.80) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL8910 0.81 TNKS (0.52) KDM4EALDH1A1TNKSMAPTCA1
SCHEMBL3079436 0.81 ERAP1 (0.58) KDM4EALDH1A1CYP1A2TNKSCA1
SCHEMBL15528314 0.80 PIK3CD (0.59) KDM4EALDH1A1TNKSMAPTCA1
SCHEMBL16584745 0.80 PIK3CD (0.59) KDM4EALDH1A1TNKSMAPTCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US claimed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2496567-B1 NOVEL BENZOPYRAN KINASE MODULATORS RHIZEN PHARMACEUTICALS S A (CH) 2017-07-12 EP disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 KDM4E 2034/4885ALDH1A1 4410/4885CYP1A2 3691/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A KDM4E 3690/4885ALDH1A1 3748/4885CYP1A2 2024/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB KDM4E 2418/4885ALDH1A1 4305/4885CYP1A2 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.